More than 2 in 5 U.S. adults, over 100 million people, now meet the clinical definition of obesity, according to the latest CDC and NHANES data. The highest prevalence sits in adults aged 40 to 59. Despite that scale, no single medication category has resolved the problem at a population level.
GLP-1 medications have reshaped the conversation, and rightly so. But the purpose of this article is to expand that conversation, not dismiss it. There is a clinical reality worth naming: a meaningful share of patients cannot take GLP-1s because of contraindications, will not stay on them (roughly 28% discontinue within the first year, and only 14.3% remain at two years in one large follow-up study), or simply cannot afford them, with out-of-pocket costs reaching as high as $1,349 per month.
For these patients, the right question is not “what is the consolation prize?” Non-GLP-1 medications are distinct tools with their own mechanisms, their own appropriate patient profiles, and their own real-world track records. The variable that most often determines whether any medication succeeds is not the drug class. It is the structure, supervision, and individualization of the program built around it.
Why Patients Arrive at This Question: The Limits of a Single-Category Approach
Patients generally arrive at the non-GLP-1 question for three reasons: medical contraindications, intolerability, and cost or access barriers.
Contraindications. GLP-1 medications are not appropriate for everyone. Absolute and relative contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, pregnancy, breastfeeding, a history of pancreatitis, severe gastroparesis, advanced kidney disease, and significant psychiatric illness.
Intolerability. Side effects were the leading reason patients stop GLP-1 therapy, accounting for 28.2% of all discontinuations in one large analysis. Nausea, vomiting, and GI distress cause many patients to stop before therapeutic benefit is realized.
Cost and access. Medicare and Medicaid do not currently cover GLP-1s for weight loss. Monthly costs can reach $1,349 before insurance, and supply and coverage inconsistencies have left patients mid-treatment without access.
Obesity medicine guidelines from bodies like the Obesity Medicine Association treat obesity as a chronic disease requiring long-term, individualized, multi-modal management, not a single-drug prescription. Seen that way, “what else exists?” is not a fallback. It is the correct clinical question. The answer is more substantive than most patients realize: over 160 obesity drugs were in development in 2025 across 68 mechanisms of action.
FDA-Approved Non-GLP-1 Weight Loss Medications: A Clinical Overview
This is a clinical survey, not a ranked list. Each medication has a distinct mechanism, an appropriate patient profile, and a real-world evidence base. A landmark JAMA meta-analysis demonstrated that all major FDA-approved non-GLP-1 agents outperformed placebo at 52 weeks, with phentermine-topiramate achieving the highest odds of meaningful weight loss.
Phentermine/Topiramate Extended-Release
This combines a sympathomimetic appetite suppressant with an anticonvulsant that reduces appetite and increases satiety. In the JAMA meta-analysis, it produced the highest odds of achieving at least 5% weight loss, with about 75% of participants reaching that threshold. It is approved for adults and adolescents aged 12 and older.
It is appropriate for patients without cardiovascular contraindications who are not pregnant (topiramate is teratogenic and requires REMS enrollment) and without glaucoma or hyperthyroidism. It carries more contraindications than some alternatives and requires careful screening and ongoing monitoring, reinforcing the need for supervised programs.
Naltrexone/Bupropion
This medication modulates reward and appetite pathways in the brain. Naltrexone blocks opioid receptors involved in food reward, while bupropion acts on dopamine and norepinephrine to reduce cravings. In the JAMA meta-analysis, about 55% of participants achieved at least 5% weight loss, and it has no abuse potential.
It is particularly relevant for patients with food-reward-driven or emotional eating, where cravings rather than appetite alone are the primary barrier. It is contraindicated in patients with seizure disorders, uncontrolled hypertension, eating disorders, or opioid use, and it carries a black-box warning for suicidal thoughts (a bupropion class effect). It addresses the behavioral and neurological dimensions of weight, not just caloric intake.
Orlistat
A gastrointestinal lipase inhibitor, orlistat blocks roughly 30% of dietary fat absorption. It is the only weight loss medication available both by prescription and over the counter. In the JAMA meta-analysis, about 49% of participants achieved at least 5% weight loss.
It suits patients who prefer a non-systemic, non-CNS-active medication. GI side effects (oily stools, fecal urgency) are common and tied directly to dietary fat intake, so adherence to a low-fat diet and fat-soluble vitamin supplementation are important. Its efficacy is the most modest among FDA-approved options, but it remains a meaningful tool for the right patient.
Phentermine
A sympathomimetic amine, phentermine suppresses appetite by stimulating norepinephrine release in the hypothalamus. It is FDA-approved for short-term use only (up to 12 weeks) and is one of the oldest, most widely prescribed appetite suppressants in the U.S.
It is a Schedule IV controlled substance, appropriate for short-term appetite suppression in otherwise healthy adults without cardiovascular disease, hyperthyroidism, glaucoma, or substance use history. It is often used as a bridge medication or as a component of a broader program rather than a standalone long-term solution, which underscores why program structure matters.
Off-Label Options with Clinical Relevance: Metformin
Metformin is not FDA-approved for weight management, but it is used off-label, particularly in insulin-resistant patients (prediabetes, PCOS, type 2 diabetes). It reduces hepatic glucose production, improves insulin sensitivity, and may modestly reduce appetite, producing roughly 2 to 5% body weight reduction on average over 6 to 12 months.
At $10 to $30 per month, it is among the most accessible pharmacologic options. The Cleveland Clinic Journal of Medicine (2023) notes that metformin is the only pharmacologic weight-loss intervention with demonstrated long-term effects and recommends it as an off-label initial therapy or adjunct. It is not a primary weight loss agent for most patients, but it is a meaningful adjunct in the right metabolic context. This reflects a broader point: the non-GLP-1 toolkit extends beyond weight loss drugs into metabolic medicine more broadly.
The Emerging Non-GLP-1 Pipeline: Scientific Validation of a Growing Field
The non-GLP-1 space is an active frontier, not a fallback. Consider eloralintide, an investigational once-weekly selective amylin receptor agonist with a non-GLP-1 mechanism. Amylin is a pancreatic hormone that regulates satiety, gastric emptying, and glucagon secretion, offering a mechanistically distinct pathway. Phase 2 data published in The Lancet (November 2025) showed dose-dependent weight loss with reportedly lower GI side effects than GLP-1 agents, and Phase 3 trials were initiated in late 2025 and early 2026.
More broadly, over 160 obesity drugs were in development in 2025 across 68 mechanisms of action, including amylin agonists and glucagon receptor agonists. As a market signal, non-GLP-1 obesity drug sales are forecast to surge from about $310 million in 2026 to $15.5 billion globally by 2031, a nearly 50-fold increase. These mechanisms confirm that GLP-1 was never the only scientifically credible pathway. (These emerging agents are not yet available clinically.)
Why Medication Category Is Not the Primary Variable: The Case for Program Structure
The regain problem makes this concrete. BMJ data published in January 2026 indicated that patients who stop GLP-1 injections tend to regain weight substantially faster than those who stop conventional dieting and exercise. Monotherapy also has limited efficacy partly because the body recruits counter-regulatory pathways, which is why a multi-target approach may provide greater benefit.
The right question, then, is not “which medication?” It is “which medication, in what combination, for which patient, within what program structure, with what monitoring?” This is where clinical experience, longitudinal patient data, and in-person oversight become the differentiating variables.
How a Multi-Tool, Supervised Program Changes the Outcome Equation
A supervised, multi-modal program adds what a prescription alone cannot: individualized assessment, ongoing monitoring, side-effect management, muscle preservation support, nutrient balance, and behavioral accountability.
Weight loss without structured support, particularly on aggressive caloric restriction, can cost patients lean muscle mass. Rapid weight loss and appetite suppression from any medication class can compromise micronutrient intake. The leading reason patients fail any medication program is rarely the medication itself. It is the absence of support and course-correction when challenges arise.
Red Mountain organizes its work into a care architecture built for exactly this: Foundation (correcting the root metabolic problem), Function (restoring how the body works, including hormone optimization), and Maintenance (protecting results over the long term). With more than 30 years of real-world patient outcomes and in-person clinical oversight, the practice can assess, adjust, and respond in real time, which is distinct from app-based or mail-order models.
Red Mountain’s RM3®: A Proprietary Non-GLP-1 Program With a Clinical Track Record
RM3® is Red Mountain’s legacy, patented program. It is not a medication alone but a three-step protocol combining a proprietary twice-daily tablet, an individualized low-calorie diet plan, and medically supervised support. The tablet is designed to help mobilize stored fat as an energy source, working in concert with the dietary protocol rather than as a standalone pharmacologic agent.
Because RM3® is formulated exclusively for Red Mountain, it does not experience the same supply shortages as brand-name treatments, a meaningful advantage for patients who have encountered access disruptions. Within Red Mountain’s broader portfolio, which also includes RM Lifestyle and RM Flex (semaglutide-based), RM3® reflects a clinical reality: no single medication category fits all patients. Red Mountain has operated since 1997, so RM3® predates the GLP-1 era and has been refined through more than three decades of real-world patient data. It is not a consolation prize. It is a clinically refined program with its own legitimate patient profile.
Matching the Right Tool to the Right Patient: What Clinical Assessment Actually Looks Like
Non-GLP-1 medication selection begins with a comprehensive assessment, not a category preference. Key variables include medical history and contraindications, metabolic markers (insulin resistance, thyroid function, hormonal status), eating behavior patterns (appetite-driven versus reward-driven), cardiovascular health, psychiatric history, cost constraints, and patient goals.
Different profiles map to different tools. A patient with insulin resistance and PCOS may benefit from metformin as an adjunct. A patient with food-reward-driven eating may be better served by naltrexone/bupropion. A patient seeking a structured, non-GLP-1 proprietary program may fit RM3®. For many patients, particularly perimenopausal and menopausal women, weight resistance is not primarily a medication problem. It is a hormonal and metabolic problem requiring assessment beyond pharmacotherapy. StatPearls and the Obesity Medicine Association both emphasize that the future of obesity pharmacotherapy lies in personalized selection based on patient characteristics, not one-size-fits-all prescribing.
What to Expect From Non-GLP-1 Programs: Setting Realistic Clinical Expectations
Non-GLP-1 medications generally produce more modest weight loss than the highest-efficacy GLP-1 agents in head-to-head comparisons. But efficacy is not the only variable that determines outcomes. Even a 5 to 10% body weight reduction produces measurable improvements in blood pressure, insulin sensitivity, and cardiovascular risk.
Outcomes depend heavily on program adherence, dietary structure, behavioral support, and monitoring. A patient who completes a supervised non-GLP-1 program with behavioral and dietary integration may sustain results more durably than a patient who takes a higher-efficacy medication without structural support. Because weight regain is a real risk after stopping any medication without a maintenance plan, Red Mountain’s Maintenance stage exists precisely to protect that investment. The goal is not the fastest number on the scale. It is a corrected metabolic foundation that supports sustained health over years.
Conclusion: The Question Was Never Which Drug, It Was Which Program
The weight loss medication landscape extends far beyond GLP-1s. The non-GLP-1 toolkit, from FDA-approved agents and off-label options to proprietary programs and an expanding pipeline, is clinically substantive, not a fallback. The right medication is the one matched to the right patient within the right program structure, with the right oversight.
GLP-1 medications have meaningfully advanced obesity medicine. But the 28% one-year discontinuation rate, the cost barriers, the contraindication profile, and the regain data after stopping all confirm that no single category is the complete answer. Red Mountain’s 30-plus years of clinical experience, in-person oversight, proprietary programs like RM3®, and a care architecture designed for long-term metabolic correction reflect a different philosophy: sustainable metabolic health is built through individualized assessment, the right combination of tools, and ongoing support that no app or mail-order prescription can replicate.
Is a Non-GLP-1 Program Right for You? Here’s How to Find Out
If you have been told you are not a GLP-1 candidate, cannot afford or access one, or have stopped a GLP-1 and are wondering what comes next, you are not out of options. The right answer is different for every patient, and finding it requires a clinician who will assess the full picture rather than default to the most-prescribed option.
That is what a consultation is for: a review of the patient’s history, metabolic picture, and which tools are actually appropriate given their current situation. It is an information-gathering step, not a commitment. Red Mountain’s programs, including RM3®, are available through brick-and-mortar clinics with in-person providers. A consultation is usually the right next step.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
